top of page
Insights for Life Sciences Talent Leaders
Strategic guidance on life sciences executive recruitment and human capital for search partners, biotech innovators, and scale-up HR leaders. I also share occasional personal reflections on the industry.


From Engineers to AI Experts: The Changing Talent Needs of MedTech
My work has spanned the medical device and diagnostics sectors, supporting senior leaders across Europe and global programmes. Assignments have included work with Software Directors, Affiliate General Managers, Heads of Division, Global Programme and Asset Management leaders, and Chief Operating Officers. The therapeutic areas covered include heart failure, hepatology, and wound management. This breadth has given me exposure to both regional and global perspectives across a r
sharonshieldsconsu
7 days ago3 min read


Q3 MedTech Earnings: Procedure-Driven Growth Meets Capital-Spending Pressure
Q3 2026 medtech results showed a widening gap between fast-growing innovators and companies facing pressure in key product lines. Abbott led among larger players, while Profound Medical and IRadimed posted strong growth from smaller bases. MiMedx and Dentsply Sirona struggled with revenue declines, highlighting how product mix and demand can shape performance across the sector.
sharonshieldsconsu
Nov 123 min read


How AI Is Transforming Clinical Development Drug Discovery Recruitment and Trial Management
Clinical development has always carried a painful contradiction. Science can point to promising biology, yet turning that promise into a tested therapy can take years of trial design, patient matching, site coordination and regulatory work. Many compounds fail late. Many trials struggle to enrol. Many teams spend too much time searching for patterns that sit hidden in papers, scans, genomic files and electronic health records.
sharonshieldsconsu
Oct 239 min read


Autumn Inflection Point: Approvals, AI, & Capital Put Life Sciences in Overdrive
Autumn inflection point: approvals, AI, and capital are putting life sciences into overdrive. As summer turns to fall, the sector is accelerating, not slowing—driven by a cluster of FDA approvals in high‑unmet‑need diseases, breakthrough gene therapies, new guidance for AI‑enabled and microbiome-based technologies, and rising deal and funding activity. For biopharma leaders and investors, this late‑summer surge signals a pivotal moment to engage, partner, and deploy capital a
sharonshieldsconsu
Aug 296 min read
bottom of page